Close Menu

NEW YORK (GenomeWeb) – Evotec announced today that it has acquired a non-exclusive license to CRISPR-Cas9 genome-editing technology from the Broad Institute and Harvard University.

Under the terms of the deal, Evotec may use the technology for its drug-development and R&D activities, including in the development of research tools and in target identification, as well as to strengthen its post-phenotypical screening target deconvolution platform. 

Additional terms of the arrangement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

As we enter conference season, Nature News asks why graduate students and postdocs are sometimes forced to choose between paying the rent and paying to attend important meetings.

A new analysis says that a 2018 study claiming to show biparental mtDNA inheritance has several flaws.

In PNAS this week: a genome sequence analysis of Crucihimalaya himalaica, multicellularity and fruiting body development in mushroom-forming fungi, and more.

Two researchers are calling for education for scientists on defending facts.